Searched for
VIATRIS API BUSINESS
Carlyle Group portfolio companies in advanced talks for a potential mergerSequent Scientific, which is in animal health business, posted revenue of around Rs 1,400 crore in FY24. It had earnings before interest, t...- Biocon arm's growth formula: US rollouts & debt reductionBiocon Biologics planned to introduce six new biosimilar products in the US in the next two years, subject to regulatory approval. They emp...
- Biocon Biologics to raise debt of Rs 4,500 crore for Viatris PayoutBiocon Biologics plans to raise ₹4,500 crore with HSBC and MUFG's aid for a $175 million Aflibercept option. Previous funding by Kotak and ...
- Kotak Alt invests Rs 1445 crore for the acquisition of Viatris' API business by Matrix PharmaKotak Alternate Asset Managers has announced a Rs 1,445 crore investment in the acquisition of Viatris' active pharmaceutical ingredient (A...
- Biocon Q4 Results: Net profit drops 57% to Rs 136 croreTotal revenue grew 1% YoY to Rs 3,966 crore. EBITDA for the quarter declined 16% YoY to Rs 964 crore, representing an EBITDA margin of 24% ...
- Edelweiss fund to back Matrix Lab founder's buyout of Viatris API bizKotak is lending $150 million (₹1,250 crore) under a mezzanine debt facility to Prasad at 18-20% and arranging an additional $300 million f...
- Kotak Fund to part finance matrix lab founder's Viatris buyThe fund plans to provide a $150 million mezzanine debt facility at 18-20% and arrange another $300 million from other lenders to finance t...
- Biocon Q3 Results: PAT at Rs 660 crore vs Rs 42-crore loss a year agoThe company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded...
- Biocon denies plans to sell $1.5 billion generic API businessBiocon API business: Biocon has refuted claims of considering the sale of its generic active pharmaceutical ingredient (API) business, valu...
- Biocon weighs sale of $1.5 billion generic API businessThe Kiran Mazumdar-Shaw helmed company made a huge bet on biosimilars by acquiring a portfolio of drugs from global drug major Viatris for ...
- Biocon Q2 Results: Profit zooms 168% YoY to Rs 126 crore; revenue jumps 49%EBITDA for the quarter increased by 68% YoY to Rs 900 crore, representing an EBITDA margin of 25% versus 22% in the same period last year. ...
- Kotak Fund to invest ₹1,600 crore in Nimmagadda Prasad's API businessKotak Strategic Situations Fund (KSSF) plans to invest around ₹1,600 crore in the active pharmaceutical ingredients (API) business acquired...
- Matrix Laboratories founder buys back API Biz from ViatrisNimmagadda Prasad, the founder of Matrix Laboratories, has bought back the active pharmaceutical ingredients (API) business he sold to Myla...
- Matrix Labs founder buys back Viatris' API business in IndiaViatris' latest transaction includes three manufacturing sites and a R&D lab in Hyderabad, three manufacturing sites in Vizag and third-par...
- Biocon Q1 Results: Profit drops 30% YoY to Rs 101 crore, revenue jumps 59%The company attributed the drop in net profit to depreciation, amortisation and interest increase of Rs 353 crore over last year primarily ...
- Viatris puts India API business on the blockHowever, the API sale process, which was launched a couple of months ago, has seen no serious buyers, added multiple people aware of the de...
- Kotak fund invests Rs 1070 crore in BioconEshwar Karra, CEO – Kotak Special Situations Fund at Kotak Investment Advisors said, We are delighted to partner with Biocon and this acqui...
- Biocon Q2 Results: Net profit drops 66% YoY to Rs 47 cr due to exceptional itemsTotal revenues rose 23% YoY for Q2FY23 at Rs 2,384 crore compared to Rs 1,945 crore in Q2FY22
- Hold Biocon, target price Rs 380: ICICI DirectBiocon, incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 44314.15 crore) operating in Pharmaceuticals secto...
- Market movers: Biocon plunges 11%, Shankara Building jumps 10%When Biocon said it will buy US-based Viatris Inc's biosimilars business in a transaction valued at $3.34 billion that will increase debt o...
Load More
